The ₹30.5 Crore Quarter: Integration Stalls, Margins Collapse
Revenue grew 14.9% year-on-year, but profit fell 70.5% quarter-on-quarter to a distressing 1.1% net margin. Management reaffirmed full-year guidance without uplift—a defensive move that signals execution challenges ahead.
₹30.5 Cr
-70.5% QoQ
1.1%
vs 3.7% Q1
₹2,743 Cr
+14.9% YoY
6.7%
EBITDA 9% (pigment)
On the topline, Sudarshan delivered headline growth: ₹2,743 crore revenue, +14.9% year-on-year. But the quarter-on-quarter PAT collapse—from ₹103 crore in Q1 to ₹30.5 crore in Q2, a 70.5% drop—tells the real story. Net margin compressed to 1.1%, down from 3.7% last quarter. This is not a one-time item. It is operational distress.
Where the profit fell
Three forces hit the quarter simultaneously. First, RIECO—the German specialty-pigments arm in the Acquired Group—turned negative, posting ₹-3 crore EBITDA in Q2 after showing 6.1% EBITDA margin in H1. Management blamed supply-chain bottlenecks and execution delays. Second, project cost overruns in backward-integration initiatives. Management flagged 'two late-stage projects' with cost overruns but offered no quantification. Third, macro headwinds persisted: US housing and European construction remained weak, customer destocking continued, and Masterbatch demand stayed volatile due to oil-price swings. The result was total pigment EBITDA of ₹242 crore on revenue of ₹2,695 crore—a 9% margin, down from prior period despite integration synergies that were supposed to begin.
Management's claims vs. what holds up
H1 Legacy Sudarshan business grew 22% revenue, +36.5% EBITDA
SupportedH1 Legacy: ₹1,636 Cr revenue (+22% YoY), ₹243 Cr EBITDA (+36.5% YoY) — accurate
EBITDA margin at Legacy level is healthy at 15.6%
Supported₹243 Cr EBITDA / ~₹1,551 Cr revenue = 15.7% — accurate
Acquired Group showing consistent performance, strong value capture underway
OverstatedH1 Acquired Group: ₹3,935 Cr revenue, 6.1% EBITDA margin, but RIECO Q2 negative ₹-3 Cr EBITDA — consistency absent
Total pigment global business showing healthy EBITDA of ₹242 Cr
Contradicted₹242 Cr EBITDA is only 9% margin on ₹2,695 Cr revenue, down from ₹327 Cr prior — margin deteriorating despite synergies
Q2 strong growth; external challenges being navigated
OverstatedRevenue +14.9% YoY but PAT -70.5% QoQ to 1.1% NPM — headline growth masks operational collapse
What changed on this call
One. Integration hitting harder than guided. Management had implied (via Q1 run-rates) that total pigment EBITDA margin would trend toward 12%+ by mid-year. Q2 delivered 9%, with RIECO turning negative. SAP implementation is only 2 of 130 applications live, and backward-integration projects are 'underway' but not yet commercialized. Cost synergies promised at 300–400 basis points have no timeline and no prior-to-new bridge in the numbers.
Two. Guidance reaffirmed defensively, not confidently. EUR 700 million Acquired Group revenue and EUR 35 million EBITDA were 'reaffirmed, no revision' despite Q1 beating expectations. This phrasing signals caution, not conviction. When a company beats and doesn't raise, the street should read it as 'near-term headwinds expected.' Management explicitly said 'revisit guidance after Q2' given geopolitical uncertainty, then did not revise. That is a defensive hold.
Three. VP4 divestiture closed post-quarter. EUR 75.8 million from the aluminum dyes toll-manufacturing business (closed Nov 2, 2026). Proceeds earmarked for debt reduction. This signals balance-sheet focus over growth capex—consistent with caution on macro.
H1 Legacy business +22% revenue, 15.6% EBITDA margin — best-in-class and growing
PAT collapsed -70.5% QoQ to 1.1% NPM despite +14.9% YoY revenue — operational distress
RIECO (Acquired Group) turned negative EBITDA Q2 after 6.1% H1 — integration friction
Total pigment EBITDA margin 9%, down from prior despite claimed synergies — synergies lagging
Guidance reaffirmed but not raised despite Q1 beat — defensive, not confident
New product pipeline (heavy metal-free dyes, digital inks, recycled plastics) in scale-up
Long-term 7× EBITDA target quantified (₹1,400+ Cr) with cost-synergy levers identified
Macro headwinds (US housing, European construction, Masterbatch volatility) persisting — near-term ceiling
Risks, ranked by how much they should concern a holder
RIECO turnaround stalls or worsens
HighQ2 negative EBITDA (₹-3 Cr) after H1 6.1% signals integration friction is real. If RIECO doesn't recover by H2, EUR 35M EBITDA guidance becomes untenable. RIECO is a material profit lever.
Macro headwinds (US, Europe, Masterbatch) persist longer than expected
HighManagement explicitly cited these as near-term brakes and hasn't revised guidance, implying weakness through FY27. If destocking takes longer or US/European demand stays soft, RIECO recovery gets delayed and market-share regain stalls.
Cost synergies and margin bridge unproven or delayed
HighManagement promised 300–400 basis points margin swing from backward integration, AI, manufacturing, procurement. But Q2 margin was 9% (vs. implied 12%+). SAP is 2/130 live. If synergies slip into FY28, near-term guidance becomes optimistic.
Project cost overruns recur or are larger than disclosed
MediumManagement flagged 'two late-stage projects' with cost overruns but did not quantify. If overruns repeat or are larger, PAT could remain compressed. Forward guidance assumes these are one-time.
Net debt trajectory deteriorates despite VP4 divestiture
MediumNet debt is ₹580 Cr H1. VP4 proceeds will reduce it, but if RIECO negative EBITDA persists and capex accelerates (backward integration), debt could rebound. Long-term 'debt-free trajectory' pledge would be at risk.
How the street is positioned
Price action and technicals: Stock closed at ₹1,155.25, neutral positioning. It sits 7% above the 20-day moving average (₹1,078.51), above the 200-day (₹994.4), but just below the 50-day (₹1,157.94)—mixed technicals with no strong directional bias. RSI at 56.5 is neutral. The stock has recovered 59% from its 52-week low (₹726.4) but remains 27.93% below its all-time high of ₹1,603. The tape is calm; the market has not panicked on the Q2 miss, nor rushed to buy the execution story.
Institutional flows: FII ownership at 8.84%, up 37 basis points QoQ—marginal add. DII at 27.90%, up 148 basis points QoQ—stronger accumulation. DII is now the largest owner. Promoter holdings at 9.32%, up 113 basis points QoQ, but down sharply from 16.40% in Q1 FY26—indicating major dilution over the past year. In August, promoter-linked entities (Rathi family) sold approximately 15.5 million shares at ₹1,015–₹1,030 per share (aggregate ~₹15.5 crore). This is modest in quantum but notable given the promoter stake has shrunk significantly. Interpretation: institutions are nibbling (DII especially), but promoters have been net sellers and remain under-committed relative to prior years.
1 · RIECO turnaround visible by Q3 FY27
Can RIECO return to positive EBITDA and get back toward the 6% margin promised in H1? This is the single biggest make-or-break for near-term guidance credibility. If Q3 RIECO EBITDA remains negative or flat, the EUR 35M Acquired Group target is at serious risk.
2 · SAP/backward-integration milestones materialize with margin impact
Management promised cost synergies by FY27-end. Can SAP go from 2/130 live to at least 50% by Q3? Can backward-integration projects show concrete unit-cost reductions in the P&L? If synergies show up, Q3/Q4 EBITDA margins should stabilize and trend toward 11%–12%. If not, the 7× EBITDA long-term target loses credibility.
3 · Macro stabilization in US/Europe; customer destocking eases
US housing and European construction are outside management control, but visible improvement here (or lack thereof) will determine whether Legacy Sudarshan's +22% growth persists. If destocking ends and Masterbatch demand normalizes, Acquired Group volumes recover faster and RIECO's path to recovery shortens.
Sudarshan Chemical is mid-integration with a clean legacy-business engine (22% revenue growth, 15.6% margins) but an Acquired Group that is stumbling. The Q2 PAT collapse—from ₹103 crore to ₹30.5 crore—is not a one-off. It is a signal that cost synergies are lagging and that macro headwinds (US, Europe, RIECO execution) are tighter than guidance implies. Management's defensive reaffirmation of EUR 700M/EUR 35M EBITDA and refusal to raise despite a Q1 beat is the clearest signal that the company is hunkering down for a weaker H2.
The near-term story is execution risk. The long-term story (7× EBITDA, debt-free, cost synergies materializing) is still intact but heavily contingent on RIECO recovery and macro stabilization. Holders should monitor Q3 RIECO EBITDA and SAP/backward-integration progress closely. If both lag, guidance itself becomes vulnerable.
The number to track from here: Total pigment EBITDA margin. It needs to climb from 9% (Q2) toward 11%–12% by Q3-Q4 for the guidance to hold. Margin stagnation signals structural integration challenges and would warrant a downgrade.
Informational and educational content only. Not investment advice.